Phase Ib/II Platform study of Multiple Anti-Cancer Agents in Participants with Metastatic Prostate Cancer

Trial Identifier: D7642C00001
Sponsor: AstraZeneca
Start Date: June 2026
Primary Completion Date: September 2029
Study Completion Date: September 2029
Condition: Prostate Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AU North Adelaide, AU, 5000
DE Essen, DE, 45147
DE Jena, DE, 07747
DE Rostock, DE, 18057
DE Tübingen, DE, 72076
ES Barcelona, ES, 08028
ES L'Hospitalet de Llobregat, ES, 08908
ES Madrid, ES, 28031
ES Madrid, ES, 28041
ES Pamplona, ES, 31008
GB Fulham, GB, SW3 6JJ
GB Guildford, GB, CU2 7XX
GB London, GB, WC1E 6DB
GB Newcastle upon Tyne, GB, NE7 7DN
GB Oxford, GB, OX3 7LE
IT Bergamo, IT, 24127
IT Meldola, IT, 47014
IT Milano, IT, 20141
IT Milano, IT, 20133
IT Roma, IT, 00168
KR Seoul, KR, 03722
KR Seoul, KR, 06351
KR Seoul, KR, 5505
KR Seoul, KR, 06591
KR Seoul, KR, 03080
US, CA Encino, CA, US, 91436
US, CA South Pasadena, CA, US, 91030
US, FL Tampa, FL, US, 33612
US, Florida Miami, Florida, US, 33165
US, LA Metairie, LA, US, 70006
US, MN Minneapolis, MN, US, 55455
US, NE Omaha, NE, US, 68130
US, NY New York, NY, US, 10065
US, OR Portland, OR, US, 97239
US, TX Houston, TX, US, 77030